Literature DB >> 30522935

Can corticosteroids reduce the mortality of patients with severe sepsis? A systematic review and meta-analysis.

Yue-Nan Ni1, Yuan-Ming Liu2, Yi-Wei Wang1, Bin-Miao Liang1, Zong-An Liang3.   

Abstract

BACKGROUND: The effects of corticosteroids on clinical outcomes of patients with sepsis remains controversial. We aimed to further determine the effectiveness of corticosteroids in reducing mortality in adult patients with severe sepsis by comparison with placebo.
METHODS: Pubmed, Embase, Medline, Cochrane Central Register of Controlled Trials (CENTRAL) as well as the Information Sciences Institute (ISI) Web of Science were searched for all controlled studies that compared corticosteroids and placebo in adult patients with severe sepsis. The primary outcome was the mortality 28-day mortality and the secondary outcomes were mortality at longest follow up, occurrence, and reoccurrence of septic shock.
RESULTS: A total of 19 trials involving 7035 patients were pooled in our final analyses. No significant heterogeneity was found in any of the outcome measures. Compared with placebo, corticosteroids were associated with a lower 28-day mortality (RR 0.91, 95% CI 0.85-0.98, Z = 2.57, P = 0.01) both in patients having sepsis and in those who developed septic shock (RR 0.92, 95% CI 0.85-0.99, Z = 2.19, P = 0.03), while no significant difference was found in mortality with the longest follow up in patients either having sepsis (RR 0.94, 95% CI 0.89-1.00, Z = 1.93, P = 0.05), or occurrence (RR 0.83, 95% CI 0.56-1.24, Z = 0.90, P = 0.37) or reoccurrence of septic shock (RR 1.08, 95% CI 1.00-1.16, Z = 1.89, P = 0.06).
CONCLUSIONS: Corticosteroids were effective in reducing the 28-day mortality in patients with severe sepsis and in those with septic shock.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Corticosteroids; Mortality; Sepsis; Septic shock

Mesh:

Substances:

Year:  2018        PMID: 30522935     DOI: 10.1016/j.ajem.2018.11.040

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  7 in total

1.  Efficacy and safety of corticosteroids in immunocompetent patients with septic shock.

Authors:  Xin Lu; Wei Han; Yan-Xia Gao; Shi-Gong Guo; Shi-Yuan Yu; Xue-Zhong Yu; Hua-Dong Zhu; Yi Li
Journal:  World J Emerg Med       Date:  2021

2.  Hydrocortisone with fludrocortisone for septic shock: a systematic review and meta-analysis.

Authors:  Ryo Yamamoto; Isao Nahara; Mitsunobu Toyosaki; Tatsuma Fukuda; Yoshiki Masuda; Seitaro Fujishima
Journal:  Acute Med Surg       Date:  2020-09-01

3.  Corticosteroids for treating sepsis in children and adults.

Authors:  Djillali Annane; Eric Bellissant; Pierre Edouard Bollaert; Josef Briegel; Didier Keh; Yizhak Kupfer; Romain Pirracchio; Bram Rochwerg
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

4.  Impact and Beneficial Critical Points of Clinical Outcome in Corticosteroid Management of Adult Patients With Sepsis: Meta-Analysis and GRADE Assessment.

Authors:  Lu-Lu Lin; Hui-Yun Gu; Jie Luo; Long Wang; Chao Zhang; Yu-Ming Niu; Hong-Xia Zuo
Journal:  Front Pharmacol       Date:  2019-09-24       Impact factor: 5.810

5.  Effectiveness of corticosteroids in patients with sepsis or septic shock using the new third international consensus definitions (Sepsis-3): A retrospective observational study.

Authors:  Yu-Pu Wu; Julie C Lauffenburger
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

6.  Effects of low-dose hydrocortisone and hydrocortisone plus fludrocortisone in adults with septic shock: a protocol for a systematic review and meta-analysis of individual participant data.

Authors:  Djillali Annane; Romain Pirracchio; Laurent Billot; Andre Waschka; Sylvie Chevret; Jeremy Cohen; Simon Finfer; Anthony Gordon; Naomi Hammond; John Myburgh; Balasubramanian Venkatesh; Anthony Delaney
Journal:  BMJ Open       Date:  2020-12-02       Impact factor: 2.692

Review 7.  Targeting the DNA repair enzymes MTH1 and OGG1 as a novel approach to treat inflammatory diseases.

Authors:  Stella Karsten
Journal:  Basic Clin Pharmacol Toxicol       Date:  2022-06-24       Impact factor: 3.688

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.